Results of Corneal Collagen Cross-linking in Pediatric Patients

Arora, Ritu; Gupta, Deepa; Goyal, Jawahar Lal; Jain, Parul

doi:10.3928/1081597x-20121011-02

Cited by 113 publications

(74 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A 3-year follow-up after epi-off CXL showed significant improvement in both visual acuity and keratometric values and a reduction in coma aberrations. Similarly, positive results were demonstrated in two smaller prospective pediatric trials [139,140]. …”

Section: Resultsmentioning

confidence: 89%

Corneal Collagen Crosslinking: A Systematic Review

Sorkin

Varssano²

2014

Ophthalmologica

160

122

View full text Add to dashboard Cite

Keratoconus (KCN) is an ectatic disorder with progressive corneal thinning and a clinical picture of corneal protrusion, progressive irregular astigmatism, corneal fibrosis and visual deterioration. Other ectatic corneal disorders include: post-LASIK ectasia (PLE) and pellucid marginal degeneration (PMD). Corneal crosslinking (CXL) is a procedure whereby riboflavin sensitization with ultraviolet A radiation induces stromal crosslinks. This alters corneal biomechanics, causing an increase in corneal stiffness. In recent years, CXL has been an established treatment for the arrest of KCN, PLE and PMD progression. CXL has also been shown to be effective in the treatment of corneal infections, chemical burns, bullous keratopathy and other forms of corneal edema. This is a current review of CXL - its biomechanical principles, the evolution of CXL protocols in the past, present and future, indications for treatment, treatment efficacy and safety.

show abstract

Section: Resultsmentioning

confidence: 89%

Corneal Collagen Crosslinking: A Systematic Review

Sorkin

Varssano²

2014

Ophthalmologica

160

122

View full text Add to dashboard Cite

show abstract

“…5,17,152 Eyes with more advanced keratoconus show more flattening during the first year. 136 A longer-term study followed patients for three years, finding that, despite the initial improvement in parameters during the first year, some pediatric patients may continue to progress long term.…”

Section: Pediatric Keratoconusmentioning

confidence: 97%

Corneal cross-linking

Randleman

Khandelwal

Hafezi

2015

Survey of Ophthalmology

156

113

View full text Add to dashboard Cite

Since its inception in the late 1990s, corneal cross-linking has grown from an interesting concept to a primary treatment for corneal ectatic disease worldwide. Using a combination of ultraviolet-A light and a chromophore (vitamin B2, riboflavin), the cornea can be stiffened, usually with a single application, and progressive thinning diseases such as keratoconus arrested. Despite being in clinical use for many years, some of the underlying processes, such as the role of oxygen and the optimal treatment times, are still being worked out. More than a treatment technique, corneal cross-links represent a physiological principle of connective tissue, which may explain the enormous versatility of the method. We highlight the history of corneal cross-linking, the scientific underpinnings of current techniques, evolving clinical treatment parameters, and the use of cross-linking in combination with refractive surgery and for the treatment of infectious keratitis.

show abstract

“…All authors reported stabilization or flattening of corneal keratometry and stabilization or improvement of visual acuity after standard epi-off procedure. Long-term comparative analysis showed that functional results after CXL among pediatric and young patients (up to 26 years) were better than in patients over 27 years [22][23][24][25][26][27][28][29][30][31][32][33][34][35][36][37][38][39] .…”

Section: Standard Procedures and Clinical Resultsmentioning

confidence: 99%

Corneal Collagen Crosslinking with Riboflavin and Ultraviolet - A Irradiation in the Management of Progressive Ectatic Corneal Disorders. Review Article

Eldine

2017

Journal of Ophthalmology and Related Sciences

View full text Add to dashboard Cite

Corneal crosslinking (CXL) has been proposed as a new modality to stop progression of keratoconus or secondary corneal ectasia, aiming to prevent progressive visual loss and to delay or avoid corneal transplantation. The possibility of strengthening corneal tissue by means of a photochemical reaction of corneal collagen by the combined action of riboflavin and ultraviolet-A irradiation (UVA), radically modified the conservative management of progressive corneal ectasia. This is a review of the state of the art of CXL. The paper describes basic principles, advantages and limitations of different CXL techniques and possible future evolution of the procedure.

show abstract

Results of Corneal Collagen Cross-linking in Pediatric Patients

Abstract: Corneal collagen CXL was found to be safe and effective in the first 12 months for keratoconus in children with similar initial efficacy as in adults in terms of improvement in visual and topographic outcomes.

Cited by 113 publications

References 16 publications

Corneal Collagen Crosslinking: A Systematic Review

Corneal Collagen Crosslinking: A Systematic Review

Corneal cross-linking

Corneal Collagen Crosslinking with Riboflavin and Ultraviolet - A Irradiation in the Management of Progressive Ectatic Corneal Disorders. Review Article

Contact Info

Product

Resources

About